Olfaction Disorders Clinical Trial
— Odorat-CovidOfficial title:
Evaluation of Two Methods of Olfactory Rehabilitation in Post-viral Loss of Smell: Classic and Intensive
NCT number | NCT04598763 |
Other study ID # | 2020PI098 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | July 1, 2020 |
Est. completion date | January 1, 2021 |
One of the most common causes of loss of smell is upper respiratory tract infection. These disorders can be quantitative (hyposmia or anosmia) or qualitative (parosmia or phantosmia). Loss of smell has been found as a major and frequent clinical sign of Sars Cov2 infection (more than 50% of patients screened at the CHU Nancy). Spontaneous recovery remains possible. It usually occurs in the first month . But when symptoms persist, the therapeutic management of post-viral anosmias is poorly codified in the literature. Olfactory rehabilitation could allow faster recovery and better quality, but the published protocols are numerous and could only be tested on small inhomogeneous series of patients (mixture of post-viral and post-traumatic hypo-ansomy). The significant increase in the population of patients suffering from post-viral anosmia following the current pandemic situation makes it possible to consider a prospective study aiming to compare two olfactory rehabilitation protocols: "classic" and "intensive" in a population of patients. suffering only from post-viral hypoanosmia. Hypothesis: Intensive or classic olfactory rehabilitation allows better results than spontaneous recovery
Status | Recruiting |
Enrollment | 80 |
Est. completion date | January 1, 2021 |
Est. primary completion date | July 1, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Major patient - Patient with a sudden loss of smell> 5 weeks linked to a viral infection (including SARS-CoV-2) of the upper respiratory tract treated in the ENT department of the CHRU Nancy - Patient accepting olfactory rehabilitation - Patient presenting with hyposmia or anosmia (confirmed by the threshold and identification tests of the Sniffin 'Stick kit) - Patient affiliated to a social security scheme or beneficiary of such a scheme - Patient who has received full research information and signed an informed consent. Exclusion Criteria: - Persons referred to in Articles L. 1121-5 to L. 1121-8 and L1122-2 of the Public Health Code: Pregnant woman, parturient or nursing mother Person deprived of liberty by a judicial or administrative decision, Person undergoing psychiatric treatment under Articles L.3212-1 and L.3213-1 of the Public Health Code Minor (non-emancipated) Adult person subject to a legal protection measure (guardianship, curatorship, safeguard of justice) Adult person unable to express consent and who is not the subject of a legal protection measure - Qualitative smell disorder (cacosmia, hyperosmia, phantosmia, parosmia) - Neurological, post-traumatic, neurodegenerative, congenital odor disorders - Post-infectious loss of smell> 12 months |
Country | Name | City | State |
---|---|---|---|
France | CHRU de Nancy | Nancy |
Lead Sponsor | Collaborator |
---|---|
Central Hospital, Nancy, France |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | improvement in smell | The change in smell is based on the comparison of the results of the olfactory assessment after / before olfactory rehabilitation obtained from a single method out of the three carried out:
Sniffin 'Stick Test Results: Threshold Test Score and Actual Identification Test Score. TI score: sum of the individual scores of the threshold and identification measures (TI score varying from 0 to 32). It is used to classify patients in terms of normosmia, hyposmia and functional anosmia based on normative values of "Sniffin 'Sticks" (according to the age and sex of each subject) with the threshold at the tenth percentile of the database provided in the study published by Hummel and Kobal. Self-assessment by patients using a digital scale of smell, from 0 (no smell) to 10 (normal smell) Self-assessment using the Dynachron-olfaction questionnaire:each question is used to assess the patient's feelings about his discomfort in the nose using a scale from 0 (no discomfort) to 10 (unbearable |
eight month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04526054 -
Morphological Abnormalities of the Olfactory Bulb on MRI and Olfactometry in Anosmic Versus Normosmic COVID-19 Patients
|
N/A | |
Recruiting |
NCT04799977 -
COVID-19: Post-covid Olfactory Disorders Assessment
|
||
Completed |
NCT04529161 -
Olfactory and Taste Changes During Fasting Mimicking Diet (FMD)
|
N/A | |
Completed |
NCT00660868 -
Is Pentoxifylline Able to Improve Olfactory Sensitivity?
|
N/A | |
Completed |
NCT04361474 -
Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity
|
Phase 3 | |
Withdrawn |
NCT01814618 -
Trial of Directed High-dose Nasal Steroids on Residual Smell Loss in Sinus Patients After Sinus Surgery
|
Phase 2 | |
Completed |
NCT03698760 -
Computerized Olfactory Test - Alzheimer Disease Mild Stage
|
N/A | |
Completed |
NCT04406584 -
Intranasal Injection of PRP Versus Saline for Treatment of Olfactory Dysfunction
|
N/A | |
Completed |
NCT02565121 -
Olfaction Disorders in Patients Included in The Trauma Brain Injury (TBI) Database at Trondheim University Hospital
|
N/A | |
Recruiting |
NCT05364125 -
Olfactory Training on Smell Dysfunction Patients in HK
|
N/A | |
Withdrawn |
NCT04696601 -
Rapid Screening for Olfactory Disorders in Covid-19 Infection
|
N/A | |
Terminated |
NCT04104594 -
Olfaction and Inflammation in Chronic Rhinosinusitis With Nasal Polyps
|
N/A | |
Withdrawn |
NCT03043144 -
Taste And Smell TEsting in End Stage Renal Disease
|
N/A | |
Recruiting |
NCT06204432 -
Sodium Citrate in Smell Retraining for People With Post-COVID-19 Olfactory Dysfunction
|
Phase 2 | |
Recruiting |
NCT04390646 -
GnRH Therapy on Cognition in Down Syndrome
|
Phase 2/Phase 3 | |
Enrolling by invitation |
NCT05666492 -
"Platelet Rich Plasma for the Management of Post-Viral Olfactory Dysfunction.
|
N/A |